Company Of The Day: Merck

October 29th, 2021 by Trefis Team
+14.81%
Upside
88.58
Market
102
Trefis
MRK: Merck logo
MRK
Merck

What?

Merck (NYSE:MRK) posted a stronger than expected set of Q3 2021 results, with revenue rising by about 20% year-over-year to $13.15 billion and adjusted EPS rising 28% to $1.75. The company also raised its full-year revenue guidance to between $47.4 billion and $47.9 billion.

Why?

Relevant Articles
  1. Is Humira Maker A Better Bet Over Merck Stock?
  2. Should You Buy Merck Stock After An Upbeat Q2?
  3. Will Merck Stock Rise After Its Q2 Results?
  4. What’s Happening With Merck Stock?
  5. Is There A Better Pick Over Merck Stock In Animal Health Space?
  6. Will Merck Stock Rise After Its Q1 Results?

Growth was driven by strong demand for drugs including Keytruda, Gardasil, and animal health products.

So What?

Merck stock gained almost 6% in Thursday’s trading.

See Our Complete Analysis For Merck

What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market consistently since 2016.

Invest with Trefis Market Beating Portfolios
See all Trefis Price Estimates